Cost-effective multiplexing before capture allows screening of 25 000 clinically relevant SNPs in childhood acute lymphoblastic leukemia

Leukemia

Volumn 25, Issue 6, 2011, Pages 1001-1006

  Wesolowska, A ^a   Dalgaard, M D ^b   Borst, L ^b   Gautier, L ^a   Bak, M ^c   Weinhold, N ^a   Nielsen, B F ^b   Helt, L R ^b   Audouze, K ^a   Nersting, J ^b   Tommerup, N ^c   Brunak, S ^a,e   Sicheritz Ponten, T ^a,f   Leffers, H ^b   Schmiegelow, K ^b,d   Gupta, R ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e University of Copenhagen   (Denmark)

^f Chalmers University of Technology   (Denmark)

Author keywords

childhood acute lymphoblastic leukemia; clinically relevant SNPs; multiplexed genotyping; next generation sequencing; target enrichment

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER SCREENING; CHILD; CHILDHOOD LEUKEMIA; COST EFFECTIVENESS ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INFANT; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT; INFANT, NEWBORN; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 79958123991     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.32     Document Type: Article

References (24)

1. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354.
2. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008; 30: 831-849.
3. Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood 2009; 113: 6077-6084.
4. Lund B, A° sberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 2011; 56: 551-559.
5. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S et al. The association of reduced folate carrier 80G4A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 2010; 115: 4671-4677.
6. Schmiegelow K, Forestier E, Kristinsson J, Soderhall S, Vettenranta K, Weinshilboum R et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 2009; 23: 557-564.
7. Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004; 22: 3930-3936. (Pubitemid 41079875)
8. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006; 34 (Database issue): D668-D672.
9. Hewett M, Oliver DE, Rubin DL, Easton KL, Stuart JM, Altman RB et al. PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res 2002; 30: 163-165. (Pubitemid 34679530)
10. Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, Rigina O et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol 2007; 25: 309-316. (Pubitemid 46402863)
11. Hiard S, Charlier C, Coppieters W, Georges M, Baurain D. Patrocles: a database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res 2010; 38 (Database issue): D640-D651.
12. Wernersson R, Juncker AS, Nielsen HB. Probe selection for DNA microarrays using OligoWiz. Nat Protoc 2007; 2: 2677-2691.
13. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215: 403-410.
14. Jiang H, Wong WH. SeqMap: mapping massive amount of oligonucleotides to the genome. Bioinformatics 2008; 24: 2395-2396.
15. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010; 26: 589-595.
16. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
17. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
18. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010; 26: 841-842.
19. Li Y, Vinckenbosch N, Tian G, Huerta-Sanchez E, Jiang T, Jiang H et al. Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet 2010; 42: 969-972.
20. Durbin RM, Abecasis GR, Altshuler DL, Auton A, Brooks LD, Durbin RM et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073.
21. Buchard A, Sanchez JJ, Dalhoff K, Morling N. Multiplex PCR detection of GSTM1, GSTT1, and GSTP1 gene variants: simultaneously detecting GSTM1 and GSTT1 gene copy number and the allelic status of the GSTP1 Ile105Val genetic variant. J Mol Diagn 2007; 9: 612-617. (Pubitemid 350158420)
22. Campana D. Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep 2010; 5: 169-176.
23. Craig DW, Pearson JV, Szelinger S, Sekar A, Redman M, Corneveaux JJ et al. Identification of genetic variants using barcoded multiplexed sequencing. Nat Methods 2008; 5: 887-893.
24. Nijman IJ, Mokry M, van BR, Toonen P, de BE, Cuppen E. Mutation discovery by targeted genomic enrichment of multiplexed barcoded samples. Nat Methods 2010; 7: 913-915.